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ABSTRACT
Introduction: Leptin is a hormone secreted by the adipocytes. 
As the periodontal breakdown increases, leptin concentration in 
serum increases with the destruction of the periodontium, but 
the evidence for this association is not so strong. So, the aim 
of our study was to evaluate the serum leptin levels in healthy, 
gingivitis and periodontitis group.
Materials and methods: Total 75 patients were selected and 
divided into three groups. Healthy (BOP < 30%, PD ≤ 4 mm), 
gingivitis (BOP ≥ 30%, PD ≤ 4 mm) and periodontitis (PD ≥ 4 mm). 
The clinical parameters that evaluated were OHI-S, PI, PD and 
% of BOP at baseline, 15 days and 1 month. Also, blood was 
collected from the anticubical fossa and was analyzed for 
Leptin ELISA test. 
Results: There was a statistically significant reduction in 
all clinical parameters at the end of 15 days and 1 month. In 
healthy group, there was strong association between OHI-S 
and serum leptin levels. Whereas in gingivitis group, there was 
a statistically significant association between OHI-S, PD and 
serum leptin levels than in periodontitis group.
Conclusion: In our study, as the periodontal disease progressed, 
there was raise in serum leptin concentration in gingivitis 
(p < 0.005) but these results did not remain consistent for 
periodontitis group. From, this we can say that for leptin to be 
an inflammatory marker and risk indicator or risk predictor in the 
progression of periodontal diseases further studies are needed. 
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INTRODUCTION
Leptin, a product of the obesity gane, is a 16-kDa non-
glyco sylated peptide hormone. It is synthesized mainly 
in adipocytes1 and, in minor quantities by placenta,2 
T cells,3 osteoblasts4 and gastric epithelium,5 which regulate 
weight control and modulate other physiological functions, 
such as regulation of neuroendocrine, reproductive and 
hemato poietic systems and bone remodeling. Recently, 
leptin has been classified as a cytokine because it shows 
structural similarities to the long-chain helical cytokine 
family, which includes interleukin-6, interleukin-11, and 
leukemia inhibitory factor.6 Moreover, leptin stimulates 
the immune system by enhancing proinflammatory 
cytokine production and phagocytosis by macrophages.7 
Therefore, during infection and inflammation, leptin 
expression is modulated in a manner similar to the 
cytokine response to infection and injury. Thus, the over-
all increase in leptin during infection and inflam mation 
indicates that leptin is part of the immune response and 
host defense mechanisms. Although, there are no adipo-
cytes in gingiva, in a recent study by Johnson and Serio,8 
it was shown that the leptin concentration is higher in 
the healthy gingiva compared with the diseased gingiva 
and they proposed that this might be caused by entrap-
ment of leptin within the gingiva by diffusion from the 
microvasculature. As leptin has a role in the inflam-
matory response, an increased leptin level in healthy 
gingiva may be a host defense mechanism similar to that 
which occurs during sepsis.9 However, during gingival 
inflammation the concentration of leptin is decreased as 
a result of expansion of the vascular network caused by 
vascular endothelial growth factor, which may increase 
the net rate of leptin removal from the gingival tissues.8 
Plasma leptin and interleukin-6 concentrations are 
reported to be elevated in acute critical illnesses, such 
as sepsis and inflammation.10 Leptin is produced by 
adipocytes. It inhibits appetite and stimulates the sympa- 
thetic nervous system, reducing adipose tissue mass. 
IL-6 is produced by immune cells and adipocytes and 
participates in the inflammatory reaction. A strong nega-
tive correlation between plasma leptin and IL-6 has been 
reported in patients experiencing a critical illness.11 The 
presence of IL-1 is essential for leptin induction, while 
IL-6 is not reported to be essential for this process.12 
Leptin stimulates the immune system, as it enhances 
cytokine production and phagocytosis by macrophages.13 
Both gingival IL-1 and IL-6 are reported to be elevated 
during progression of periodontal diseases,14 while the 
role of leptin in this progression is unknown. 
Estimation of Leptin Levels in Serum in Periodontal Health 
and Disease: A Clinical and Biochemical Study
1Dhaval Shah, 2Deepak Dave, 3Monali Shah, 4Neeraj Deshpande
JOFR
ORIGINAL RESEARCH
10.5005/jp-journals-10026-1145
1Postgraduate, 2Professor and Head, 3,4Professor
1-4Department of Periodontics, KM Shah Dental College 
Sumandeep Vidyapeeth, Vadodara, Gujarat, India
Corresponding Author: Dhaval Shah, Postgraduate 
Department of Periodontics, KM Shah Dental College 
Sumandeep Vidyapeeth, Pipariya, Vadodara, Gujarat, India 
Phone: 09925105127, e-mail: drdvshah31@yahoo.in
Estimation of Leptin Levels in Serum in Periodontal Health and Disease: A Clinical and Biochemical Study
Journal of Orofacial Research, July-September 2014;4(3):138-142 139
JOFR
Although, there are numerous studies of the rela-
tionship between inflammation, leptin metabolism and 
plasma leptin concentrations, there is no information 
available concerning the possible role of leptin in progres-
sion of inflammation within human tissues, in particular, 
gingival11,12,15-17 diseases.
However, to date, the leptin concentration in serum 
in periodontal health and disease has not been explored 
alone. Hence, this study was designed to assess the con-
centration of human leptin in serum during perio dontal 
health and disease, and, in addition, to obtain a more 
detailed insight into its possible role in the initiation and 
progression of periodontal disease.
MATERIALS AND METHODS
Study Design
1. Place of the study: Department of Periodontics, KM 
Shah Dental College and Hospital, Sumandeep Vidya-
peeth, Pipariya.
2. Source of the data: Outpatient Department of Perio-
dontics, KM Shah Dental Collage, Pipariya.
3. Related approvals: Nil.
4. Sample description: Was selected from the Outpatient 
Department of Periodontics, KM Shah Dental College.
Subjects were divided into three groups as follows:
• Group 1: Healthy gingiva (BOP ≤ 30%)
• Group 2: Moderate to severe gingivitis with BOP ≥ 
30%, PD ≤ 4 mm.
• Group 3: Periodontitis with BOP ≥ 30%, PD ≥ 4 mm
There were 25 patients in each group.
5. Selection criteria:
 1. Inclusion criteria
  • Age: 20 to 50 years
  • Subjects who have not received periodontal 
treatment in previous 6 months
  • Dentition with 20 functioning teeth
 2. Exclusion criteria
 • Patient having any systemic disease.
 • Patient taking any antibiotic/anti-inflammatory 
drugs for the past 6 months.
 • Patients with teeth which were partially erupted 
or impacted.
 • Anomalies of the immune system.
 • Pregnancy and lactation.
 • History of any influence in the inflammatory 
response.
 • Patients with the habit of smoking and alcoholism.
 • Patients with aggressive periodontitis
 • Patients with bleeding disorders.
Material/Equipment for the Study
• Mouth mirror
• William’s graduated periodontal probe
• Surgical gloves
• Mouth mask
• Disposable syringe
• Glass tubes and stand
• Human leptin ELISA Kit
• Aliquots
Storage of samples: Collected blood samples were kept 
in a serum separator tube and were allowed to clot for 30 
minutes before centrifugation for 15 minutes at 1000× g. 
after that serum was removed and Aliquoted. Storage of 
samples was at ≤–20°C. Repeated freeze-thaw cycles 
were avoided.
Methodology
Clinical Periodontal Procedure
Each patient who was enrolled in the study was exami-
ned thoroughly before commencing with scaling and 
root-planing procedure and oral hygiene instructions 
were given after the treatment. Before scaling and root 
planing, plaque index (PI) (Silness P and Loe H, 1964) 
were taken to evaluate oral hygiene maintenance of the 
patient, PPD the distance between the gingival margin 
and the bottom of the gingival pocket was measured and 
BOP (%) was measured as bleeding which occurred 
within 30 seconds of probing. All clinical recordings 
were performed immediately before the scaling and root-
planing (baseline).
Collection of Blood Sample
With patient’s consent, prior to each sample collection, 
disinfection of the skin at the site of venipuncture was 
done with surgical spirit.
After tying the tourniquet 3 to 4 inches above the ante-
cubital fossa, blood sample of 3 ml is collected from the 
antecubital vein of the forearm using 20 gauge needle and 
5 ml syringe and stored in tubes containing trisodium 
citrate anticoagulant.
Blood samples were collected before scaling and root 
planing.
Estimation of Serum Leptin Levels
Tubes with collected blood samples were sent to the 
patho logy lab within 24 hours and serum leptin was esti-
mated through ELISA test using human leptin ELISA Kit 
(Biovendor research and diagnostic products).
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RESULTS
From Table 1, it can be interpreted that there was a signi- 
ficant reduction in PI from base line to 15 days and 
1 month but there was no statistical significant difference 
between the groups. 
The estimated mean PI value with standard error was 
0.87 ± 0.113 (CI 0.65-1.1) at base line reduced to 0.73 ± 0.093 
(CI 0.54-0.91) and 0.67 ± 0.10 (CI 0.47-0.87) in healthy group, 
where in gingivitis group it was 1.5 ± 0.113 (CI 1.36 -1.8) at 
base line reduced to 1.36 ± 0.093 (CI 1.18-1.55) and 1.17 ± 
0.10 (CI 0.98-1.3) and in periodontitis group it was 1.93 ± 
0.113 (CI 1.70-2.15) at base line reduced to 1.57 ± 0.93 (CI 
0.1.38-1.75) and 1.05 ± 0.10 (CI 0.85-1.25) at 15 days and 
1 month follow-up.
The mean probing depth in healthy, gingivitis and 
perio dontitis groups was 3.58 ± 0.59 (mean SD), 3.95 ± 
0.63 and 6.29 ± 0.72, which showed significant reduction 
of 3.31 ± 0.65, 3.39 ± 0.52, 5.21 ± 0.84 at 15 days and 3.16 ± 
0.73, 3.21 ± 0.49 and 4.79 ± 0.67 at the end of 1 month.
The mean pocket depth reduction with standard 
error in healthy group was 3.58 ± 0.13 (CI 3.32-3.84) which 
reduced to 3.31 ± 0.13 (CI 3.05-3.57) and 3.16 ± 0.12 (CI 
2.91-3.42).
In gingivitis group, it reduced from 3.95 ± 0.131 (CI 
3.69-4.21) to 3.39 ± 0.13 (CI 3.13-3.65) and 3.21.12 (CI 2.95 - 
3.47). In periodontitis group, reduction was from 6.29 ± 
0.13 (CI 6.03-6.55) to 5.21 ± 0.13 (CI 4.95-5.47) and 4.79 ± 
0.128 (CI 4.53-5.04) at the end of 15 days and 1 month.
At baseline for healthy, gingivitis and periodontitis, 
it was 2.16, 7.85, 4.73, 10.23 and 4.63, 9.77. At the end of 15 
days, it reduced to 1.62, 6.24, 2.63, 12.13 and 3.33, 7.79. At 
the end of 1 month, it was 1.25, 6.57, 1.77, 10.45 and 2.32, 
7.39. 
The mean percentage of BOP with standard error 
for healthy group was 21.62, 1.87 (CI 17.89-25.34) which 
reduced to 16.23, 1.81 (CI 12.62-19.85) and 12.58, 1.66 (CI 9.26-
15.89). For gingivitis group it was 47.37, 1.87 (CI 43.64-51.10) 
which reduced to 26.37, 1.8 (CI 22.75-29.99) and 17.75, 1.66 
(CI 14.44-21.07) at the end of 15 days and 1 month.
In periodontitis group, it was 46.35, 1.87 (CI 42.64- 
50.09) which reduced to 33.30, 1.81 (CI 29.68-36.92) and 
23.24, 1.66 (CI 19.92-26.55).
Table 2 is showing the inter-relationship between all 
the clinical parameters and the serum leptin levels in 
healthy group in which only OHI-S is significantly related 
with the serum leptin levels with p = 0.03.
Table 3 is showing the inter-relationship between all 
the clinical parameters and serum leptin levels in perio-
dontitis group in which OHI-S and PD are significantly 
associated with serum leptin levels with the p-value of 
p = 0.03 with OHI-S and p = 0.01 for PD.
Table 3 is showing correlation among the all clinical 
parameters and serum leptin levels but, having a weak 
association with the serum leptin levels.
DISCUSSION
Leptin is a hormone that is secreted in the blood in 
varying quantities by adipocytes and controls the adipose 
tissue weight by stimulating lipid metabolism by the 
organism.18 Adipocytes in the obese people produce a 
large quantity of biologically active molecules, such as 
leptin, and high leptin concentration in blood has been 
suggested as a risk factor for the cardiovascular diseases.
According to Preadeep AR et al (2007),19 the uses of 
the laptin are as follows:
• It regulates weight in a central munnar by suppressing 
the hunger.
• Proliferation and differentiation of hematopoietic 
cells, angiogenesis and wound healing.
• It enhances body’s immune mechanism by indu-
cing the proliferation of human peripheral blood 
mononuclear cells, chemotaxis and oxidative species 
production by stimulated PMNs, phagocytosis by 
macrophages.
Table 1: Clinical parameters at baseline, 15 days and 1 month
 
 
 
 N
PI PD Percentage of BOP
Mean Std. deviation Mean Std. deviation Mean Std. deviation
At baseline 1 25 0.87 0.43 3.58 0.59 2.16 7.85
2 25 1.58 0.63 3.95 0.63 4.73 10.23
3 25 1.92 0.6 6.29 0.72 4.63 9.77
Total 75 1.46 0.71 4.61 1.36 3.84 15.12
 15 days 1 25 0.73 0.36 3.31 0.56 1.62 6.24
2 25 1.36 0.57 3.39 0.52 2.63 12.13
3 25 1.57 0.42 5.21 0.84 3.33 7.79
Total 75 1.22 0.58 3.97 1.09 2.53 11.39
 1 month 1 25 0.67 0.37 3.16 0.73 1.25 6.57
2 25 1.17 0.57 3.21 0.49 1.77 10.45
3 25 1.05 0.51 4.79 0.67 2.32 7.39
Total 75 0.96 0.53 3.72 0.98 1.78 9.29
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• It has direct effect on osteoblast proliferation, diffe-
rentiation and prolonging the life span of human 
primary osteoblast by inhibiting apoptosis.
• It protects the host from inflammation and infection 
and maintains the bone levels.
Till date, all the studies that have taken place for the 
estimation of the leptin were the combinations of the 
leptin levels either in gingival biopsies or in GCF and 
serum/plasma concentration of leptin.
The studies which were associating a direct significant 
relationship with the advancement of periodontitis and 
serum leptin levels were rare and hardly took place. So, 
in our study, we tried to establish a direct relationship 
between the serum concentration of leptin and periodontal 
disease progression.
Here, the results are showing significant reduction 
in all the clinical parameters at the end of 15 days and 
1 month follow-up. 
Zimmermann et al (2013)20 concluded that perio-
dontitis mainly influenced the circulating levels of 
resistin and adiponectin, whereas both obesity and perio-
dontitis affected the circulating levels of leptin in favor 
of proinflammation. In addition, obesity upre gulated the 
local levels of TNF-a.
When we tried to find correlation among all the clini-
cal parameters and serum leptin levels in all the three 
Table 2: Healthy group 
  Age OHI-S PI at baseline PD at baseline BOP% at baseline Serum leptin levels
Age  1 –0.4 0.002 –0.016 –0.245 –0.202
p-value  0.042 0.991 0.941 0.237 0.332
N 25 25 25 25 25 25
OHI-S  –0.409* 1 0.468* 0.302 0.207 0.424*
p-value 0.042  0.018 0.143 0.321 0.035
N 25 25 25 25 25 25
PI at baseline  0.002 0.468* 1 –0.052 –0.104 0.37
p-value 0.991 0.018  0.805 0.621 0.069
N 25 25 25 25 25 25
PD at baseline  –0.016 0.302 –0.052 1 0.111 0.263
p-value 0.941 0.143 0.805  0.597 0.204
N 25 25 25 25 25 25
BOP% at baseline  –0.245 0.207 –0.104 0.111 1 –0.038
p-value 0.237 0.321 0.621 0.597  0.858
N 25 25 25 25 25 25
Serum leptin levels  –0.202 0.424* 0.37 0.263 –0.038 1
p-value 0.332 0.035 0.069 0.204 0.858  
N 25 25 25 25 25 25
*Correlation significant at p-value ≤ 0.05
Table 3: Gingivitis group
  Age OHI-S PI at baseline PD at baseline BOP% at baseline Serum leptin levels
Age  1 –0.29 0.201 –0.226 0.085 –0.323
p-value  0.159 0.336 0.278 0.687 0.115
N 25 25 25 25 25 25
OHI-S  –0.29 1 0.094 0.478* 0.056 0.572**
p-value 0.159  0.655 0.016 0.791 0.003
N 25 25 25 25 25 25
PI at baseline  0.201 0.094 1 0.12 0.097 0.028
p-value 0.336 0.655  0.566 0.643 0.894
N 25 25 25 25 25 25
PD at baseline  –0.226 0.478* 0.12 1 –0.274 0.607**
p-value 0.278 0.016 0.566  0.185 0.001
N 25 25 25 25 25 25
BOP% at baseline  0.085 0.056 0.097 –0.274 1 –0.043
p-value 0.687 0.791 0.643 0.185  0.839
N 25 25 25 25 25 25
Serum leptin levels  –0.323 0.572** 0.028 0.607** –0.043 1
p-value 0.115 0.003 0.894 0.001 0.839  
N 25 25 25 25 25 25
*Correlation significant at p-value ≤ 0.05; **Correlation siginificant at p-value ≤0.01
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groups. In group 1 (healthy group), we found significant 
association between OHI-S and PI with p < 0.01 and OHI-S 
and serum leptin with p < 0.03. Where as in group 2 
(gingivitis group), serum leptin levels were significantly 
associated with OHI-S with p < 0.03 and pocket depth 
at baseline with p < 0.01. But, in periodontitis group, no 
significant association was found between all the clinical 
parameters and serum leptin levels.
In our study, as the periodontal disease progressed, 
there was raise in serum leptin concentration in gin-
givitis group with the p < 0.005. But, these results did not 
remained consistent for periodontitis group. From these 
results, it can be hypothesized that this new inflamma-
tory marker has the potential of being a risk indicator 
or risk predictor in the management of cardiovascular 
diseases and is having a weak association with OHI-S, 
PI and pocket depth with the significant increase of all 
these clinical parameters as the disease advances. But, it 
has to undergo further positive concrete evidences for 
being one of the same. 
CONCLUSION
There is significant increase in the serum leptin levels in 
gingivitis group patients than from the healthy group 
subjects. As the disease progressed, the increase in the 
serum leptin levels were found in gingivitis group.
Direct positive correlation exists between raise in the 
serum leptin levels and periodontal disease progression 
in healthy and gingivitis group but a weak association 
is present between serum leptin levels and periodontitis 
group. So, it can be concluded that higher levels of leptin 
can be one of the helpful diagnostic parameters in occur-
rence and progression of periodontal diseases in future. 
But, further other aspects have to be checked before 
the acceptance of these results because of the positive 
association of leptin with inflammation and obesity. So, 
further well designed studies are still needed with better 
number of sample size in future to establish a concrete 
relationship between the serum leptin and periodontitis. 
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